Abstract: Objective：To analyze the value of intravenous immunoglobulin combined with cyclosporin treatment in children with Kawasaki disease at high drug resistance risk. Methods：50 children with Kawasaki disease admitted to our hospital from July 2021 to May 2022 were randomly divided into the control group(intravenous immunoglobulin) and the study group(intravenous immunoglobulin combined with cyclosporine) to compare the effects. Results： The improvement time of clinical symptoms in the study group was shorter than that in the control group(P＜0.05). The inflammatory index in the study group was lower than that in the control group(P＜0.05)； The level of immunoglobulin in the study group was higher than that in the control group(P＜0.05). The incidence of adverse reactions in the study group was lower than that in the control group(P＜0.05). The treatment cost and hospital stay in the study group were lower than those in the control group(P＜0.05). Conclusion： In the treatment of children with Kawasaki disease at high risk of drug resistance， intravenous immunoglobulin combined with cyclosporine has a better effect， which can shorten the recovery time of children， and improve the immunoglobulin level and inflammation index of children.

Key words: font-size:medium, ">Intravenous immunoglobulin； Cyclosporin； High drug resistance risk； Kawasaki disease； Treatment effect